Last reviewed · How we verify

NCT06306222

Thulium Fiber Laser vs. Holmium:YAG Laser for the Ureteroscopic Treatment of Patients With Urinary Stone Disease

Status unknown NA Last updated 12 March 2024
What this trial tests

NA trial testing Laser lithotripsy in Kidney Stone in 120 participants. Status unknown.

Timeline
23 November 2023
Primary endpoint
23 November 2025
23 February 2026

Quick facts

Lead sponsorIRCCS San Raffaele
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment120
Start date23 November 2023
Primary completion23 November 2025
Estimated completion23 February 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

Adults 18 to 99, any sex, with Kidney Stone or Ureteral Stone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled trial which aims to compare the efficacy and safety of Thulium fiber laser (TFL) and holmium:yttrium-aluminum-garnet (Ho:YAG) laser ablation during the treatment of upper urinary tract stone disease with flexible ureteroscopy, demonstrating clinical superiority of TFL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Stone

Currently open trials in the same condition.

Other IRCCS San Raffaele trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06306222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing